Back to results
US 12,540,196 B2Granted
GPC3 binding molecules
AssigneeKite Pharma, Inc.
InventorsMatthew Drever, Gabrielle M. Romain, Sarah K. Wyman, Chi Ying
Life of this patent
Estimating the term…
Abstract
Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the GPC3 binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.
Claims116
An antibody that binds to human Glypican 3 (GPC3), wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein the VH comprises a VH complementarity determining region (CDR) 1, a VH CDR2, and a VH CDR3 of the sequence set forth in SEQ ID NO:
- 3, and the VL comprises a VL CDR1, a VL CDR2, and a VL CDR3 of the sequence set forth in SEQ ID NO:
- 14.
Dependencies are inferred from the claim text.